Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccination against COVID-19 in Pregnant and Lactating Women in Belgium
2021-000440-22Phase 4Completed
- Sponsor
- University of Antwerp
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran, elasomeran and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by University of Antwerp. Primary endpoint: Primary: Antibody-based immune response to COVID-19 vaccination. Started Feb 2021; status: completed.
02
Drugs
tozinameranelasomeranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000440-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000440-22.